Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021.

ABSTRACT:

Background

Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited. We conducted a retrospective longitudinal cohort study to assess the incidence of hospitalised infections following rituximab among children with cSLE and to assess changes in hospital-based rituximab administration over time.

Methods

Youth ages 2-21 years with an International Classification of Diseases (ICD) code for SLE who received rituximab during admission to a Pediatric Health Information System hospital from 2009 to 2021 were included. Incidence rates for infections requiring hospitalisation over the 12 months following first rituximab administration were calculated. Rituximab use by year of hospital dischar

SUBMITTER: Roberts JE 

PROVIDER: S-EPMC11407221 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature